Results 111 to 120 of about 72,428 (200)
Small Science, EarlyView.Herein, a liver‐targeted nanohybrid formulation, SGLC/DOX@AG, is developed to enhance doxorubicin delivery and reduce vascular toxicity in hepatocellular carcinoma (HCC) treatment. Incorporating an albumin–glucosamine lipid complex, the system shows potent anticancer effects and minimized side effects across in vitro, in vivo, and cancer‐on‐a‐chip ...
Hyelim Kim +11 more
wiley +1 more source
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Acta Pharmacologica Sinica, 2017 Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the treatment of advanced renal cell carcinoma in 2006, and as a unique target drug for
Yan-jing Zhu +3 more
semanticscholar +1 more source
VIEW, EarlyView.Angiogenesis is an essential process in tissue regeneration, as it prevents complications such as necrosis, inflammation, and fibrosis. mADM decellularized by the supercritical carbon dioxide method exhibits high preservation of the extracellular matrix and various growth factors.
Hyo‐Jin Kim +14 more
wiley +1 more source
Organoid‐based novel technology for antitumor drug screening
VIEW, EarlyView.Organoids represent a cutting‐edge research model that closely mimics in vivo organ physiology, making them highly valuable for tumor immunotherapy drug screening. This review explores the integration of organoids with advanced technologies, such as gene editing, 3D bioprinting, and AI, highlighting novel fusion platforms and their applications.
Yu Su +3 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu +9 more
wiley +1 more source
Cancer Science, EarlyView.circNEK11 is overexpressed in human HCC tissues, especially in recurrent tissues, and promotes the oncogenic functions of HCC cells. circNEK11 interacted with miR‐1236‐3p to stimulate GPX2 expression. Our findings highlight the potential of circNEK11 as a biomarker for HCC diagnosis and suggest that targeting circNEK11 may be an effective strategy for ...
Qian Li +10 more
wiley +1 more source
European Journal of Clinical Investigation, EarlyView.Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano +15 more
wiley +1 more source
Hepatology Research, EarlyView.ABSTRACT Background Atezolizumab plus bevacizumab (AB) is a standard first‐line therapy for unresectable hepatocellular carcinoma (HCC). However, data on the efficacy and safety of AB rechallenge (re‐AB) after discontinuation are limited. Methods We conducted a retrospective analysis of 13 patients with unresectable HCC who received initial AB ...
Yuichiro Suzuki +13 more
wiley +1 more source
Hepatology Research, EarlyView.ABSTRACT Background and Aims The relationship between oxidative stress (OS) and hepatocellular carcinoma (HCC) is well known, influencing both, hepatocarcinogenesis and subsequent tumor progression. Less understood is its potential role in antitumor defense mechanisms.
Víctor Merino +7 more
wiley +1 more source